NCT00047190

Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia

A Phase II Trial of R115777 in Myelofibrosis With Myeloid Metaplasia (MMM)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: National Cancer Institute (NCI) · NIH
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Phase II trial to study the effectiveness of tipifarnib in treating patients who have myelofibrosis with myeloid metaplasia. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.

Detailed description

PRIMARY OBJECTIVES: I. To evaluate the response rate in MMM patients treated with R115777. II. To evaluate the toxicity of R115777 in patients with MMM. SECONDARY OBJECTIVES: I. To evaluate the benefit of therapy with R115777 in alleviating disease-associated anemia in patients with MMM. II. To evaluate the benefit of R115777 in reducing palpable splenomegaly in patients with MMM. III. To evaluate the effect of R115777 on the hypercatabolic symptoms from MMM. IV. To evaluate the effect of R115777 on the pathologic increase in circulating myeloid progenitors in MMM patients through baseline measurement and measurement after the first cycle. V. To correlate response/relapse with in vitro myeloid colony sensitivity to R115777 at the time of either response or relapse. VI. To evaluate the effect of R115777 on bone marrow histologic features of MMM including osteosclerosis, reticulin fibrosis, and angiogenesis (through serial bone marrow microvessel density grading). OUTLINE: This is a multicenter study. Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months until disease progression and then every 6 months for up to 2 years. PROJECTED ACCRUAL: A total of 18-35 patients will be accrued for this study within 15 months.

Conditions

• Essential Thrombocythemia
• Polycythemia Vera
• Primary Myelofibrosis

Interventions

Type	Name	Description
DRUG	tipifarnib	Given PO
OTHER	laboratory biomarker analysis	Correlative studies

Timeline

• Start date: 2002-08-01
• Primary completion: 2007-04-01
• First posted: 2003-01-27
• Last updated: 2013-06-04

Locations

1 site across 1 country: United States